Outset Medical (NASDAQ:OM - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($1.76) per share and revenue of $29.40 million for the quarter. Outset Medical has set its FY 2025 guidance at EPS.
Outset Medical (NASDAQ:OM - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($3.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($2.69). Outset Medical had a negative return on equity of 143.62% and a negative net margin of 98.74%. The company had revenue of $29.75 million for the quarter, compared to the consensus estimate of $27.81 million.
Outset Medical Stock Performance
NASDAQ:OM traded down $1.02 during mid-day trading on Friday, hitting $15.04. 449,042 shares of the company's stock traded hands, compared to its average volume of 274,001. The firm has a 50 day moving average of $19.10 and a two-hundred day moving average of $14.48. Outset Medical has a 12 month low of $5.85 and a 12 month high of $53.92. The firm has a market capitalization of $266.51 million, a price-to-earnings ratio of -0.52 and a beta of 2.14. The company has a current ratio of 8.37, a quick ratio of 6.74 and a debt-to-equity ratio of 0.57.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on OM shares. Scotiabank upgraded Outset Medical to a "strong-buy" rating in a research note on Thursday, May 15th. Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $21.00 price target (up previously from $14.00) on shares of Outset Medical in a report on Wednesday, May 21st. Finally, BTIG Research set a $37.00 price target on Outset Medical and gave the company a "buy" rating in a report on Monday, July 14th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $29.50.
Check Out Our Latest Stock Analysis on OM
About Outset Medical
(
Get Free Report)
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Read More
Before you consider Outset Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.
While Outset Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access